Have a feature idea you'd love to see implemented?
Let us know!
CDTX Cidara Therapeutics Inc
Price (delayed)
$17.45
Market cap
$122.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$25.92
Enterprise value
-$479,254
Cidara Therapeutics Inc. isa is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its
Highlights
CDTX's debt is down by 10% YoY and by 8% QoQ
Cidara Therapeutics's quick ratio has soared by 101% YoY but it has decreased by 31% from the previous quarter
The EPS has dropped by 181% year-on-year
The gross profit has plunged by 61% YoY and by 44% from the previous quarter
Key stats
What are the main financial stats of CDTX
Market
Valuations
Earnings
Shares outstanding
7.05M
Market cap
$122.96M
Enterprise value
-$479,254
Price to earnings (P/E)
N/A
Price to book (P/B)
1.06
Price to sales (P/S)
4.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.02
Revenue
$26.35M
EBIT
-$123.07M
EBITDA
-$121.86M
Free cash flow
-$160.15M
Per share
Balance sheet
Liquidity
EPS
-$25.92
Free cash flow per share
-$24.52
Book value per share
$16.43
Revenue per share
$4.03
TBVPS
$24.86
Total assets
$162.33M
Total liabilities
$46.7M
Debt
$3.94M
Equity
$115.63M
Working capital
$112.43M
Debt to equity
0.03
Current ratio
3.54
Quick ratio
2.91
Net debt/EBITDA
1.01
Margins
Efficiency
Dividend
EBITDA margin
-462.5%
Gross margin
89.8%
Net margin
-467.3%
Operating margin
-493.9%
Return on assets
-108.1%
Return on equity
-223.3%
Return on invested capital
N/A
Return on capital employed
-104.3%
Return on sales
-467.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CDTX stock price
How has the Cidara Therapeutics stock price performed over time
Intraday
15.41%
1 week
20.51%
1 month
55.53%
1 year
19.11%
YTD
9.89%
QTD
62.33%
Financial performance
How have Cidara Therapeutics's revenue and profit performed over time
Revenue
$26.35M
Gross profit
$23.65M
Operating income
-$130.14M
Net income
-$123.13M
Gross margin
89.8%
Net margin
-467.3%
Cidara Therapeutics's operating margin has shrunk by 105% QoQ
CDTX's net margin has shrunk by 80% QoQ
The gross profit has plunged by 61% YoY and by 44% from the previous quarter
The company's revenue has shrunk by 56% YoY and by 41% QoQ
Growth
What is Cidara Therapeutics's growth rate over time
Valuation
What is Cidara Therapeutics stock price valuation
P/E
N/A
P/B
1.06
P/S
4.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.02
The EPS has dropped by 181% year-on-year
CDTX's equity is down by 12% since the previous quarter
CDTX's price to sales (P/S) is 154% higher than its last 4 quarters average of 1.7 and 31% higher than its 5-year quarterly average of 3.3
The company's revenue has shrunk by 56% YoY and by 41% QoQ
Efficiency
How efficient is Cidara Therapeutics business performance
Cidara Therapeutics's return on assets has shrunk by 88% YoY but it has increased by 17% QoQ
The return on sales has dropped by 80% since the previous quarter
Cidara Therapeutics's return on equity has increased by 47% YoY and by 46% QoQ
Dividends
What is CDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CDTX.
Financial health
How did Cidara Therapeutics financials performed over time
The total assets has soared by 156% YoY but it has contracted by 6% from the previous quarter
CDTX's current ratio has surged by 119% year-on-year but it is down by 17% since the previous quarter
CDTX's debt is 97% lower than its equity
Cidara Therapeutics's debt to equity has plunged by 94% YoY
CDTX's equity is down by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.